Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

EXPLAINED: Mirati therapeutics s return on capital employed overview | Rare Historical Photos

Benzinga Pro data, Mirati Therapeutics (NASDAQ:MRTX) reported Q4 sales of $299.00 thousand. Earnings fell to a loss of $199.62 million, resulting in a 149.36% decrease from last quarter. Mirati Therapeutics collected $71.79 million in revenue during Q3, but reported earnings showed a $80.05 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.